Epi-LASIK is a surface treatment procedure that provides options for patients who were previously not good candidates for LASIK.
Epi-LASIK, which features the Epikeratome System, is U.S. Food and Drug Administration (FDA) 510(k)-approved and a European CE certified instrument. With this new system, surgeons can reduce the chance of post-surgical risks and complications associated with LASIK, such as dry eye.
This technology also offers new surgical vision correction options for patients who have been non-candidates for LASIK due to dry eyes, thin corneas or high myopia.
In traditional LASIK surgery, a flap is created with the use of a blade or laser. The Epi-LASIK system utilizes a separator rather than a blade to create a thin sheet of surface cells and eliminates the need for alcohol or other chemical agents, which can be toxic to the cornea. Because of this, complications sometimes associated with the blade, such as flap complications or aberrations induced by the flap, can be eliminated. Following the application of the laser correction to the cornea, the thin sheet is returned to its original position.
Custom or wavefront-guided laser treatments are best when coupled with the Epi-LASIK surface treatment rather than the flap-based technology because of the reduced risk of flap induced aberrations.